GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Creo Medical Group PLC (STU:1RC) » Definitions » Return-on-Tangible-Asset

Creo Medical Group (STU:1RC) Return-on-Tangible-Asset : -35.74% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Creo Medical Group Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Creo Medical Group's annualized Net Income for the quarter that ended in Dec. 2023 was €-23.45 Mil. Creo Medical Group's average total tangible assets for the quarter that ended in Dec. 2023 was €65.61 Mil. Therefore, Creo Medical Group's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -35.74%.

The historical rank and industry rank for Creo Medical Group's Return-on-Tangible-Asset or its related term are showing as below:

STU:1RC' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -178.49   Med: -47.92   Max: -26.85
Current: -40.59

During the past 9 years, Creo Medical Group's highest Return-on-Tangible-Asset was -26.85%. The lowest was -178.49%. And the median was -47.92%.

STU:1RC's Return-on-Tangible-Asset is ranked worse than
73.11% of 859 companies
in the Medical Devices & Instruments industry
Industry Median: -2.69 vs STU:1RC: -40.59

Creo Medical Group Return-on-Tangible-Asset Historical Data

The historical data trend for Creo Medical Group's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Creo Medical Group Return-on-Tangible-Asset Chart

Creo Medical Group Annual Data
Trend Feb14 Feb15 Feb16 Jun17 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only -30.91 -25.84 -39.45 -47.28 -44.49

Creo Medical Group Semi-Annual Data
Feb14 Feb15 Feb16 Dec16 Jun17 Dec17 Jun18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.90 -43.07 -49.42 -42.43 -35.74

Competitive Comparison of Creo Medical Group's Return-on-Tangible-Asset

For the Medical Devices subindustry, Creo Medical Group's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Creo Medical Group's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Creo Medical Group's Return-on-Tangible-Asset falls into.



Creo Medical Group Return-on-Tangible-Asset Calculation

Creo Medical Group's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-25.188/( (54.731+58.502)/ 2 )
=-25.188/56.6165
=-44.49 %

Creo Medical Group's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=-23.448/( (72.721+58.502)/ 2 )
=-23.448/65.6115
=-35.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2023) net income data.


Creo Medical Group  (STU:1RC) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Creo Medical Group Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Creo Medical Group's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Creo Medical Group (STU:1RC) Business Description

Traded in Other Exchanges
Address
Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy.

Creo Medical Group (STU:1RC) Headlines

No Headlines